Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis.
Kalincik T, Jokubaitis V, Izquierdo G et al.
Royal Melbourne Hospital, Parkville, VIC, Australia.
Mult Scler 2015;21:1159–71.
Melinda Magyari’s review: Observational studies comparing disease-modifying treatments (DMTs) in the treatment of relapsing–remitting multiple sclerosis (MS) in real-world settings have made an important contribution to the body of evidence supporting the efficacy and safety of DMTs that was established by randomized clinical trials. Head-to-head comparisons of DMTs are few, and the four currently approved injectable medications are considered comparable to each other in terms of the efficacy measures of relapse rate and disability progression in clinical practice.